266 related articles for article (PubMed ID: 27786169)
21. Lithium and antidepressants: potential agents for the treatment of Rett syndrome.
Tsai SJ
Med Hypotheses; 2006; 67(3):626-9. PubMed ID: 16584849
[TBL] [Abstract][Full Text] [Related]
22. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.
Ben-Zeev B; Aharoni R; Nissenkorn A; Arnon R
Med Hypotheses; 2011 Feb; 76(2):190-3. PubMed ID: 20951500
[TBL] [Abstract][Full Text] [Related]
23. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients.
Lilja T; Wallenborg K; Björkman K; Albåge M; Eriksson M; Lagercrantz H; Rohdin M; Hermanson O
Epigenetics; 2013 Mar; 8(3):246-51. PubMed ID: 23348913
[TBL] [Abstract][Full Text] [Related]
24. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
Gadalla KK; Bailey ME; Cobb SR
Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
[TBL] [Abstract][Full Text] [Related]
25. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression.
Chang Q; Khare G; Dani V; Nelson S; Jaenisch R
Neuron; 2006 Feb; 49(3):341-8. PubMed ID: 16446138
[TBL] [Abstract][Full Text] [Related]
26. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains.
Itoh M; Ide S; Takashima S; Kudo S; Nomura Y; Segawa M; Kubota T; Mori H; Tanaka S; Horie H; Tanabe Y; Goto Y
J Neuropathol Exp Neurol; 2007 Feb; 66(2):117-23. PubMed ID: 17278996
[TBL] [Abstract][Full Text] [Related]
27. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution.
Kaufmann WE; Johnston MV; Blue ME
Brain Dev; 2005 Nov; 27 Suppl 1():S77-S87. PubMed ID: 16182491
[TBL] [Abstract][Full Text] [Related]
28. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice.
Kline DD; Ogier M; Kunze DL; Katz DM
J Neurosci; 2010 Apr; 30(15):5303-10. PubMed ID: 20392952
[TBL] [Abstract][Full Text] [Related]
29. Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: a possible approach for the treatment of Rett syndrome.
Tsai SJ
Med Sci Monit; 2012 Aug; 18(8):HY33-36. PubMed ID: 22847207
[TBL] [Abstract][Full Text] [Related]
30. Restoring Wnt6 signaling ameliorates behavioral deficits in MeCP2 T158A mouse model of Rett syndrome.
Hsu WL; Ma YL; Liu YC; Tai DJC; Lee EHY
Sci Rep; 2020 Jan; 10(1):1074. PubMed ID: 31974426
[TBL] [Abstract][Full Text] [Related]
31. Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: insights into Rett syndrome.
Lioy DT; Wu WW; Bissonnette JM
Auton Neurosci; 2011 Apr; 161(1-2):55-62. PubMed ID: 21316312
[TBL] [Abstract][Full Text] [Related]
32. Early intervention with psychostimulants or antidepressants to increase methyl-CpG-binding protein 2 (MeCP2) expressions: a potential therapy for Rett syndrome.
Pan CH; Tsai S
Med Sci Monit; 2012 Jan; 18(1):HY1-3. PubMed ID: 22207122
[TBL] [Abstract][Full Text] [Related]
33. Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome.
Matagne V; Borloz E; Ehinger Y; Saidi L; Villard L; Roux JC
Neurobiol Dis; 2021 Feb; 149():105235. PubMed ID: 33383186
[TBL] [Abstract][Full Text] [Related]
34. Affective dysfunction in a mouse model of Rett syndrome: Therapeutic effects of environmental stimulation and physical activity.
Kondo MA; Gray LJ; Pelka GJ; Leang SK; Christodoulou J; Tam PP; Hannan AJ
Dev Neurobiol; 2016 Feb; 76(2):209-24. PubMed ID: 26019053
[TBL] [Abstract][Full Text] [Related]
35. Metabolomic Fingerprint of Mecp2-Deficient Mouse Cortex: Evidence for a Pronounced Multi-Facetted Metabolic Component in Rett Syndrome.
Golubiani G; Lagani V; Solomonia R; Müller M
Cells; 2021 Sep; 10(9):. PubMed ID: 34572143
[TBL] [Abstract][Full Text] [Related]
36. Loss of MeCP2 disrupts cell autonomous and autocrine BDNF signaling in mouse glutamatergic neurons.
Sampathkumar C; Wu YJ; Vadhvani M; Trimbuch T; Eickholt B; Rosenmund C
Elife; 2016 Oct; 5():. PubMed ID: 27782879
[TBL] [Abstract][Full Text] [Related]
37. Selective preservation of cholinergic MeCP2 rescues specific Rett-syndrome-like phenotypes in MeCP2
Zhou H; Wu W; Zhang Y; He H; Yuan Z; Zhu Z; Zhao Z
Behav Brain Res; 2017 Mar; 322(Pt A):51-59. PubMed ID: 28093257
[TBL] [Abstract][Full Text] [Related]
38. The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome.
Nectoux J; Bahi-Buisson N; Guellec I; Coste J; De Roux N; Rosas H; Tardieu M; Chelly J; Bienvenu T
Neurology; 2008 May; 70(22 Pt 2):2145-51. PubMed ID: 18434641
[TBL] [Abstract][Full Text] [Related]
39. Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism.
Swanberg SE; Nagarajan RP; Peddada S; Yasui DH; LaSalle JM
Hum Mol Genet; 2009 Feb; 18(3):525-34. PubMed ID: 19000991
[TBL] [Abstract][Full Text] [Related]
40. Regulation mechanism and research progress of MeCP2 in Rett syndrome.
Yang W; Pan H
Yi Chuan; 2014 Jul; 36(7):625-30. PubMed ID: 25076025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
